Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancer

Bitget2026/10/08 20:12

Guardant Health secured EU CE-marking for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant). Test targets ESR1 mutations in ER-positive, HER2-negative advanced breast cancer to guide treatment selection via blood-based liquid biopsy. Clearance marks Guardant’s 31st companion diagnostic approval, following prior U.S. and Japan authorizations for ETCAMAH. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610081612BIZWIRE_USPR_____20261008_BW669405) on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq

Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.

智通财经•2026/11/09 06:12

UniCredit: Third-quarter net profit reaches 3.26 billion euros, exceeding expectations

格隆汇•2026/11/09 06:11

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45